Key Highlights
- RXST shares fell approximately 3% in pre-market trading to $5.43, down from a prior close of $5.60.
- The company lowered preliminary second-quarter sales guidance to $110 million to $120 million, below its previous range of $120 million to $135 million.
- Gross margin guidance was raised to 73% to 75%, above the prior range of 70% to 72%.
- Separately, RxSight announced a non-exclusive collaboration with Alcon that includes a $60 million upfront payment and up to $140 million in additional milestone payments.
Guidance Cut Overshadows Alcon Partnership
RxSight, Inc. (NASDAQ:RXST) shares moved lower in pre-market trading after the company issued preliminary second-quarter results that included a reduction to its sales guidance, even as it simultaneously announced a new collaboration agreement with Alcon. RxSight is an ophthalmic medical device company headquartered in Aliso Viejo, California, known for its Light Adjustable Lens system, the only commercially available intraocular lens technology that can be adjusted after cataract surgery.
The company now expects preliminary second-quarter sales of $110 million to $120 million, below the $120 million to $135 million range it had previously guided to. Operating expense is expected to land at the high end of the prior $150 million to $160 million range. The company noted these figures remain preliminary estimates pending completion of its quarterly financial statements and review by its independent auditor, with full results due after market close on August 5, 2026.
Alcon Collaboration Terms
Alongside the guidance update, RxSight and Alcon (SIX/NYSE:ALC) announced a non-exclusive agreement to jointly develop adjustable presbyopia-correcting intraocular lenses, combining RxSight's post-operative light-adjustable technology with Alcon's optical lens designs. RxSight will receive a $60 million upfront payment to begin development work, with the potential for up to $140 million in additional payments tied to development and regulatory milestones. Alcon will lead global commercialization under the agreement, while RxSight retains responsibility for development and manufacturing and will receive royalties on net sales.
RxSight carries a market capitalization of approximately $231.8 million following the pre-market move, with shares trading within a 52-week range of $4.48 to $13.36. The stock does not currently carry a price-to-earnings ratio given ongoing losses.
Conclusion
The market reaction suggests investors are weighing the near-term guidance reduction more heavily than the longer-dated upside from the Alcon partnership and improved gross margin outlook. Investors will likely watch the finalized second-quarter results due in August, along with any early progress updates on the Alcon collaboration, for further clarity on the trajectory of both the core Light Adjustable Lens business and the new partnership revenue stream.
FAQs
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...